Search results
Results from the WOW.Com Content Network
Danaher reported second-quarter adjusted EPS of $1.71, beating the consensus of $1.57. ... DANAHER (DHR): Free Stock Analysis Report. This article Life Science Giant Danaher Q3 Earnings: ...
Danaher (DHR) delivered earnings and revenue surprises of 14.29% and 8.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
On Tuesday, Danaher Corp (NYSE:DHR) reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the consensus of $5.59 billion. Guidance: Danaher reaffirms that in fiscal year ...
Danaher (DHR) Q4 results to reflect gains from better-than-expected segmental top-line performances, mainly Diagnostics and Life Sciences. Cost inflation is likely to have been affecting margins.
Danaher's (DHR) Q3 results are expected to reflect a healthy demand for products in Life Sciences and Diagnostics segments. Also, Cytiva is anticipated to have aided core sales.
Danaher's (DHR) Q3 results reflect growth in Life Sciences and Diagnostics segments' sales, contribution from Cytiva, and operating margin rise. Core Q4 sales are likely to grow in high-single digits.
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.